您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (6): 81-86.doi: 10.6040/j.issn.1671-7554.0.2018.1481

• 临床医学 • 上一篇    下一篇

肺癌患者18F-FDG PET/CT SUVmax与程序性死亡受体-配体1表达相关性的Meta分析

陈红艳1,马园园2,孙虎魁2   

  1. 1.山东省胸科医院呼吸科, 山东 济南250013;2.淄博市中心医院核医学科, 山东 淄博255000
  • 发布日期:2022-09-27
  • 通讯作者: 孙虎魁. E-mail:hukui.s@sdu.edu.cn
  • 基金资助:
    国家自然科学基金(81601535);中国博士后面上项目(2017M612287)

Correlation between SUVmax of 18F-FDG PET/CT and programmed cell death-ligand 1 expression in lung cancer patients: a Meta-analysis

CHEN Hongyan1, MA Yuanyuan2, SUN Hukui2   

  1. 1. Respiratory Department, Chest Hospital of Shandong Province, Jinan 250013, Shandong, China;
    2. Nuclear Medicine Department, Central Hospital of Zibo, Zibo 255000, Shandong, China
  • Published:2022-09-27

PDF (PC)

68

摘要： 目的 运用Meta分析方法综合评价肺癌患者PET/CT检查18F-FDG摄取(FDG-PET)定量参数SUVmax值与肿瘤程序性死亡受体-配体1(PD-L1)表达的相关性。 方法 检索 PubMed、Medline、Cochrane图书馆、中国知网、万方数据库收录的 2000年1月至2018年12月公开发表的关于肺癌患者PET/CT扫描后肿瘤局部摄取18F-FDG定量参数SUVmax值与肿瘤PD-L1表达相关性的中英文文献,提取文献中的相关系数(r值)及相关数据,使用Comprehensive Meta-Analysis软件进行Meta分析。使用Jadad量表对纳入的文献进行质量评估。 结果 共4篇文献符合纳入标准,均为英文SCI文献,样本量共1 033例。Meta分析结果显示,通过合并Spearman相关系数(r值)进行分析,SUVmax值与PD-L1表达呈弱正相关(r=0.289,95%CI:0.100~0.459,P<0.001)。亚组分析显示鳞癌和腺癌(非小细胞肺癌)均呈现相似的弱正相关趋势(r=0.235, P=0.011; r=0.273, P=0.003),均有统计学意义。 结论 肺癌摄取FDG的SUVmax值与PD-L1表达呈正相关性,鳞癌和腺癌均呈现相同趋势;FDG-PET定量参数SUVmax值可以为临床PD-1靶向治疗筛选患者和判断预后提供一定的影像学依据。

关键词: 肺癌, 程序性死亡受体-配体1, SUVmax, Meta分析, Spearman相关系数

Abstract: Objective To study the correlation between 18F-FDG uptake and programmed cell death-ligand 1(PD-L1)expression in lung cancer patients by Meta-analysis of published articles. Methods According to the literature inclusion and exclusion criteria, PubMed(MEDLINE included), EMBASE, and Cochrane Database of Systematic Review were searched, and research articles on the relationship between 18F-FDG uptake and PD-L1 expression, which were published between January 1, 2000 and Decenber 1, 2018, were selected. The quality of included articles was evaluated according to the Jadad scale. The correlation coefficient(r)was extracted from the included articles. The combined r and the 95% confidence interval (CI) were calculated with Comprehensive Meta-Analysis software under a random-effects model. Results According to the inclusion and exclusion criteria, 4 articles, involving 1033 patients, were finally included. All the studies had a combined r value of 0.289(95%CI: 0.100~0.459, P<0.001), but with a significant 山 东 大 学 学 报 (医 学 版)57卷6期 -陈红艳,等.肺癌患者18F-FDG PET/CT SUVmax与程序性死亡受体-配体1表达相关性的Meta分析 \=-heterogeneity(I2=86%, P=0.003). Subgroup analysis for different tumor types indicated that adenocarcinomas and squamous cell carcinomas showed a positive correction(r=0.273, P=0.003; r=0.235, P=0.001). Conclusion SUVmax positively correlates with PD-L1 expression for patients with lung cancer, and the similar trend is found in both adenocarcinomas and squamous cell carcinomas. The assessment of SUVmax value and PD-L1 immunohistochemistry score may improve the accuracy of patient selection and predicit PD-1 treatment effect.

Key words: Lung cancer, Programmed cell death-ligand1, SUVmax, Meta analysis, Spearman correlation coefficient

中图分类号: 

  • R734.2
[1] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Sher DJ, Koshy M, Liptay MJ, et al. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base[J]. Cancer, 2014, 120(13): 2060-2068.
[3] Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2.2013[J]. J Natl Compr Canc Netw, 2013, 11(6): 645-653; quiz 653.
[4] Lim SH, Sun JM, Lee SH, et al. Pembrolizumab for the treatment of non-small cell lung cancer[J]. Expert Opin Biol Ther, 2016, 16(3): 397-406.
[5] Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833.
[6] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550.
[7] Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer[J]. J Thorac Oncol, 2016, 11(7): 976-988.
[8] Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments[J]. Eur J Nucl Med Mol Imaging, 2017, 44(Suppl 1): 55-66.
[9] Higuchi M, Owada Y, Inoue T, et al. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer[J]. World J Surg Oncol, 2016, 14(1): 238. doi:10.1186/s12957-016-0998-y.
[10] Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale[J]. Control Clin Trials, 1999, 20(5): 448-452.
[11] Chalkidou A, Landau DB, Odell EW, et al. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis[J]. Eur J Cancer, 2012, 48(18): 3499-3513.
[12] Landis JR, Koch GG. The measurement of observer agreement for categorical data[J]. Biometrics, 1977, 33(1): 159-174.
[13] Lopci E, Toschi L, Grizzi F, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer(NSCLC)who are candidates for upfront surgery[J]. Eur J Nucl Med Mol Imaging, 2016, 43(11): 1954-1961.
[14] Zhang MH, Wang DL, Sun Q, et al. Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma[J]. Oncotarget, 2017, 8(31): 51630-51640.
[15] Takada K, Toyokawa G, Okamoto T, et al. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18F-fluorodeoxyglucose positron emission tomography/computed tomography[J]. Cancer Med, 2017, 6(11): 2552-2561.
[16] Kaira K, Shimizu K, Kitahara S, et al. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma[J]. Eur J Cancer, 2018, 101: 181-190. doi:10.1016/j.ejca.2018.06.022.
[17] Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies[J]. Ann Oncol, 2016, 27(1): 147-153.
[18] Cooper WA, Tran T, Vilain RE, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma[J]. Lung Cancer, 2015, 89(2): 181-188.
[19] Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol, 2017, 12(2): 208-222.
[20] Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2012, 39(1): 27-38.
[21] Choi H, Paeng JC, Kim DW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT[J]. Lung Cancer, 2013, 79(3): 242-247.
[22] Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression[J]. Clin Cancer Res, 2004, 10(15): 5094-5100.
[23] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
[24] Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer[J]. Cancer Res, 2013, 73(8): 2381-2388.
[25] Lopci E, Toschi L, Grizzi F, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer(NSCLC)who are candidates for upfront surgery[J]. Eur J Nucl Med Mol Imaging, 2016, 43(11): 1954-1961.
[1] 黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[2] 温学龙,刘安慧,陈经纬,吴梦婷,杨岷. 急性非ST抬高型心肌梗死行冠状动脉旁路移植手术时机Meta分析[J]. 山东大学学报 (医学版), 2025, 63(5): 60-70.
[3] 赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[4] 徐年兴,魏东,乔俊杰,战炳炎. CD8+、IL-6和PaO2对不可切除ⅢB/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[5] 山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[6] 李懿原,马珊,李爱华,龙飞. 超声支气管镜引导下碘-125粒子植入治疗肺癌中央区淋巴结转移[J]. 山东大学学报 (医学版), 2025, 63(12): 26-34.
[7] 刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[8] 刘向荣,张新胜,杨荩冉,杨雪艳,刘钊,刘英华. ω-6/ω-3多不饱和脂肪酸比值对不同肿瘤发病风险的系统综述和Meta分析[J]. 山东大学学报 (医学版), 2024, 62(8): 34-48.
[9] 张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[10] 王亚楠,梁传杰,贾梦琪,苑辉卿. 二硫键异构酶TMX1促进肺癌化疗耐药[J]. 山东大学学报 (医学版), 2023, 61(8): 31-39.
[11] 王蕾,向淇,刘学伍. 伴系统性硬化症、类风湿关节炎的副肿瘤神经综合征1例[J]. 山东大学学报 (医学版), 2023, 61(7): 118-120.
[12] 谢晓丽, 邱雨, 王丽娟. 干扰素-γ通过PI3K/Akt/mTOR通路上调程序性死亡受体-配体1促进非霍奇金淋巴瘤细胞增殖[J]. 山东大学学报 (医学版), 2023, 61(5): 11-19.
[13] 钟璐,薛付忠. 基于贝叶斯网络不确定性推理的肺癌风险预测模型[J]. 山东大学学报 (医学版), 2023, 61(4): 86-94.
[14] 程传龙,韩闯,房启迪,刘盈,杨淑霞,崔峰,刘靖靖,李秀君. 基于时空地理加权回归模型探索肺癌发病的环境影响因素[J]. 山东大学学报 (医学版), 2023, 61(4): 95-102.
[15] 杨咏青,赵鹏,汪玉,马文静,田迷迷,程亚旎,祖璐,林祥涛. 细胞外容积分数对62例不同病理类型肺癌的诊断价值[J]. 山东大学学报 (医学版), 2023, 61(2): 88-94.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发